Furthermore, invasion assays revealed that this treatment combination reduced the migratory behaviour of colorectal cancer cells via the inhibition of MMP-9 and C-X-C chemokine receptor type 4 (CXCR4) expression, the downregulation of NF-κB expression, and disruption of ten–eleven translocation methylcytosine dioxygenase 1 (TET1)–naked cuticle homolog 2 (NKD2)–Wnt signalling pathways [77,79]. The gene discussed is NFKB1; the disease is colorectal cancer.